Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI ... ( EXTON Pa. July 31 /- BioTrends ...)

HOME >> MEDICINE >> NEWS

Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA

Date:7/31/2009

EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends(TM): SIMPONI and CIMZIA report. The survey was completed by U.S. Rheumatologists in late June 2009.

While awareness of both new TNF antagonists is relatively high, there are some troubling signs regarding initial impressions of these agents. The initial favorability rating for Simponi, for example, has slipped from 65% in the baseline report to 41% with the current wave of research. The initial favorability rating for Cimzia was significantly lower than both the baseline and current results for Simponi.

More than one-half of surveyed physicians have prescribed Simponi while less than one-third report trial of Cimzia. Over 80% of Simponi patients were switched from other biologics (primarily Humira) while a higher percent of the Cimzia patients were biologic naive. The majority of Rheumatologists see both of these agents as second or third line biologic options for the treatment of RA.

Dosing with Cimzia appears to be both a blessing and a curse -- once monthly administration has high patient appeal, but the loading dose, large volume, two injection requirement, and potential patient confusion are also noted as product disadvantages. Simponi is viewed as being significantly easier to administer. The Rheumatologists surveyed, however, view the products as extremely similar. While both Simponi and Cimzia are expected to gain market share in the next six months, the combined share of the two agents is not expected to exceed 15% of the biologic share in Rheumatoid Arthritis.

Looking to the future, Rheumatologists report high familiarity with Roche's ACTEMRA, an IL-6 blocker in Phase III clinical trials. Unlike the established TNFs (Enbrel, Humira, and Remicade) which have been the target of Cimzia and Simponi's launches, the su
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Crowded emergency departments pose greater risks for patients with heart attacks
2. Crowded Households Raise Womens Heart Risk
3. Osteotech to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
4. Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment
5. Air Methods to Report Second Quarter Financial Results After Market Close on Thursday, August 6, 2009
6. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
7. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
8. Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market
9. NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
10. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
11. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals

Post Your Comments:

Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI ...( EXTON Pa. July 31 /- BioTrends ...),Health